C3N-01017
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 56.82683094
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.440
- MYC_TARGETS_V1+0.390
- E2F_TARGETS+0.370
- G2M_CHECKPOINT+0.330
- SPERMATOGENESIS+0.280
- OXIDATIVE_PHOSPHORYLATION+0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.170
- MTORC1_SIGNALING+0.160
- MITOTIC_SPINDLE+0.120
- KRAS_SIGNALING_DN+0.090
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.620
- INTERFERON_GAMMA_RESPONSE-0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- ANGIOGENESIS-0.500
- IL6_JAK_STAT3_SIGNALING-0.460
- INFLAMMATORY_RESPONSE-0.420
- TGF_BETA_SIGNALING-0.410
- TNFA_SIGNALING_VIA_NFKB-0.410
- COMPLEMENT-0.390
- COAGULATION-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-63-A5MY-01A-11R-A26W-07 | — | cohortSQ2 | 0.913 |
| 2 | SRR15069607 | — | — | 0.913 |
| 3 | TCGA-AN-A0AR-01A-11R-A00Z-07 | — | E | 0.912 |
| 4 | SRR8518240 | — | E | 0.912 |
| 5 | C3N-01025 | — | cohortSQ2 | 0.907 |
| 6 | C3L-01285 | — | cohortSQ2 | 0.907 |
| 7 | TCGA-AN-A04D-01A-21R-A034-07 | — | E | 0.899 |
| 8 | SRR8518239 | — | E | 0.899 |
| 9 | TCGA-56-7730-01A-11R-2125-07 | — | cohortSQ2 | 0.898 |
| 10 | TCGA-UY-A78N-01A-12R-A33J-07 | — | — | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |